Acute myocardial infarction
Drug research and approvals for acute myocardial infarction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 202 studies of acute myocardial infarction are recruiting on ClinicalTrials.gov, and Health Canada has authorized 5 drug trials for it since 2013.
- Recruiting worldwide: 202
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 202 recruiting on ClinicalTrials.gov ↗- BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac RehabilitationNCT07741396 · Not applicable · University of Illinois Chicago · starts Nov 2, 2026
- CRP Apheresis in Infarct-Related Cardiogenic ShockNCT07687017 · Not applicable · Leipzig Heart Science gGmbH · starts Oct 16, 2026
- Trends and Risk Factors of Adverse Cardiovascular and Cerebrovascular Events After Primary PCINCT07833995 · Not reported · Shanghai Zhongshan Hospital · starts Sep 28, 2026
- NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic StrokeNCT07828210 · Phase 4 · EVD Pharmacy and Medical Company Limited · starts Sep 10, 2026
- Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic ShockNCT07583446 · Phase 2 / Phase 3 · Seismic Pharmaceuticals Operations LLC · starts Sep 9, 2026
- Smartphone AI Assistance for Prehospital ECG InterpretationNCT07810686 · Not applicable · École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · starts Sep 2, 2026
- Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12…NCT07507500 · Phase 4 · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · starts Sep 2, 2026
- Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary SyndromeNCT07824323 · Phase 4 · Taipei Medical University Hospital · starts Aug 26, 2026
- Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMINCT07583784 · Not applicable · Chonnam National University Hospital · starts Aug 26, 2026
- SPIKE FLOW Endocardial Lead Safety and Performance StudyNCT07820072 · Not applicable · FIAB SpA · starts Aug 7, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Aug 22, 2023 | Randomized, double-blind, placebo-controlled study to investigate a single administration of bi 765845 on top of standard of care in patients with acute…BI 765845 | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Ongoing |
| Aug 18, 2021 | Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous…SELATOGREL (ACT-246475) | Viatris | Ongoing |
| Dec 16, 2020 | Empact-mi: a streamlined, multicentre, randomised, parallel group, doubleblind placebo-controlled superiority trial to evaluate the effect of empagliflozin on…EMPAGLIFLOZIN | Boehringer Ingelheim Pharmaceuticals, Inc. | Closed |
| Dec 8, 2016 | A multi-center, randomized, double-blind, active-controlled, parallel-group phase 3 study to evaluate the efficacy and safety of lcz696 compared to ramipril on…LCZ696 (SACUBITRIL-VALSARTAN) | Novartis Pharmaceuticals Corporation | Closed |
| Apr 23, 2014 | The safety and efficacy of ticagrelor for coronary stenting post thrombolysis, the setfast trialTICAGRELOR | DR ASIM CHEEMA | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA